Hepatitis B Vaccination (HBV) in HIV Infected Children

The HIV Netherlands Australia Thailand Research Collaboration80 enrolled

Overview

The purpose of this study is : * To evaluate prevalence of protective hepatitis B antibody comparing intradermal (ID) and intramuscular (IM) route in antiHbsAb negative HIV infected children treated with highly active antiretroviral therapy (HAART) * To revaccinate the HBV vaccine in the children who didn't have protective HBV Ab

Hepatitis B virus (HBV) and HIV share the same route of transmission and can have co-infection. The prevalence of this co-infection was 8.7% in Thai adult\[1, 2\] and 12.1% in African HIV vertically transmitted children\[3\]. Occurrence of HBV has effects to treatment due to having the same medication, lamivudine, tenofovir, emtricitabine or entecavir, to anti HIV medication. HBV can cause chronic liver disease, cirrhosis and hepatocellular carcinoma. In Thailand, the routine HBV vaccination program was started since 1992. Few reports in severe immune compromise HIV children has been shown to lose their expected preventive measles and hepatitis B antibody from history of scheduled vaccination even after the immune recovery by HAART\[4, 5\]. Limited data in of prevalence of protective hepatitis B antibody response after immune recovery in Thai HIV infected children treated with highly active antiretroviral therapy. In addition, HBV revaccination in this group of children should be considered\[6\]. The response of HBV revaccination intramuscularly (IM) at 0, 2 and 6 months in 63 HIV children shown response rates 17.4, 82.5, and 92.1% at 2, 6 and 7 months respectively\[6\]. Protective anti-HBs were shown in the majority of non-responders to IM HBV vaccine health care workers \[21/23 (91.3%)\] by two doses of intradermal route (ID)\[7\]. We hypothesize to see the faster and higher response of antiHBs after first dose of ID compare to IM in anti HBsAb negative HIV infected children. No randomized control trial compare antibody response between IM and ID route in HIV children after immune recovery. The benefit from this trial would be decreased the vaccine cost for resourced limited country.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

HIV Infections

Interventions

Intradermal HBV 1 courseBIOLOGICAL

Dosage: 2 microgram (mcg), 0.1 ml per dose Location: left deltoid area x 1 injection Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months

Intramuscular HBV I courseBIOLOGICAL

Eligibility

Sex: ALLMin age: 1 YearMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV infected individuals * Age 1-18 years * Current CD4 within 6 months ≥ 15% or ≥ 200 cells/ml in children age ≥ 6 years * Signed written informed consent * Negative HBs Ag, antiHBs, and antiHBc at screening visit Exclusion Criteria: * Active AIDS * Active opportunistic infection * Platelet \< 50,000/ mm3 at screening visit * History of hypersensitivity to HBV vaccine * Using oral steroid or immunosuppressive drugs

Locations (2)

HIV-NAT

Bangkok, Thailand

Pediatric infectious diseases section, King Chulalongkorn Memorial hospital

Bangkok, Thailand

Outcomes

Primary Outcomes

Proportion of children with protective antiHBs at 8 weeks after first dose of HBV ID is superior to HBV IM

Time frame: 8 weeks

Secondary Outcomes

Proportion of children with positive antiHBs at 4 weeks after second and third dose of HBV

Time frame: 4 weeks

Number of adverse events in HBV ID group and HBV IM group

Time frame: 7 months

Proportion of protective antiHBs in HIV children after protocol defining immune recovery

Time frame: 7 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.